Business Description
RTW Biotech Opportunities Ltd
ISIN : GG00BKTRRM22
Description
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-EBITDA | N/A |
N/A
|
N/A
| |||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 6/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year FCF Growth Rate | 81.7 | |||||
3-Year Book Growth Rate | 17.4 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 89.88 | |||||
9-Day RSI | 81.4 | |||||
14-Day RSI | 75.06 | |||||
3-1 Month Momentum % | 9.45 | |||||
6-1 Month Momentum % | 1.38 | |||||
12-1 Month Momentum % | 81.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.4 | |||||
Shareholder Yield % | 1.58 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Net Margin % | 97.73 | |||||
FCF Margin % | 41.95 | |||||
OCF Margin % | 41.95 | |||||
ROE % | 35.31 | |||||
ROA % | 28.34 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 3.92 | |||||
PE Ratio without NRI | 3.92 | |||||
PEG Ratio | 1.01 | |||||
PS Ratio | 4.52 | |||||
PB Ratio | 0.93 | |||||
Price-to-Tangible-Book | 0.93 | |||||
Price-to-Free-Cash-Flow | 9.88 | |||||
Price-to-Operating-Cash-Flow | 9.88 | |||||
EV-to-Revenue | 3.15 | |||||
EV-to-FCF | 7.52 | |||||
Price-to-Projected-FCF | 1.93 | |||||
Price-to-Graham-Number | 0.4 | |||||
FCF Yield % | 13.2 | |||||
Forward Rate of Return (Yacktman) % | 1.48 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
RTW Biotech Opportunities Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 250.886 | ||
| EPS (TTM) ($) | 0.63 | ||
| Beta | 0.0128 | ||
| 3-Year Sharpe Ratio | 0.75 | ||
| 3-Year Sortino Ratio | 1.45 | ||
| Volatility % | 21.91 | ||
| 14-Day RSI | 75.06 | ||
| 14-Day ATR ($) | 0.078779 | ||
| 20-Day SMA ($) | 2.2635 | ||
| 12-1 Month Momentum % | 81.82 | ||
| 52-Week Range ($) | 1.18 - 2.47 | ||
| Shares Outstanding (Mil) | 322.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
RTW Biotech Opportunities Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
RTW Biotech Opportunities Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-09-11 09:00 | In 71 days | ||
| Second quarter earnings results for 2026 | 2026-09-11 | In 70 days | ||
| General meeting for 2026 | 2026-06-11 13:00 | 2.18 (+3.32%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-30 09:00 | 1.91 (-1.29%) | ||
| Annual report for 2025 | 2026-03-30 | 1.91 (-1.29%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 1.91 (-1.29%) | ||
| Second quarter earnings conference call for 2025 | 2025-09-11 09:00 | 1.50 (-0.99%) | ||
| Second quarter earnings results for 2025 | 2025-09-11 | 1.50 (-0.99%) | ||
| General meeting for 2025 | 2025-06-09 14:00 | 1.17 (+0.86%) | ||
| Annual report for 2024 | 2025-03-31 | 1.21 (-0.82%) |
Show
Entries
RTW Biotech Opportunities Ltd Frequently Asked Questions
What is RTW Biotech Opportunities Ltd(LSE:RTW)'s stock price today?
The current price of LSE:RTW is $2.47. The 52 week high of LSE:RTW is $2.47 and 52 week low is $1.18.
When is next earnings date of RTW Biotech Opportunities Ltd(LSE:RTW)?
The next earnings date of RTW Biotech Opportunities Ltd(LSE:RTW) is 2026-09-11 Est..
Does RTW Biotech Opportunities Ltd(LSE:RTW) pay dividends? If so, how much?
RTW Biotech Opportunities Ltd(LSE:RTW) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on RTW Biotech Opportunities Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers